Brokerages Set Aligos Therapeutics, Inc. (NASDAQ:ALGS) Price Target at $38.50

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $38.50.

Several equities research analysts have recently commented on ALGS shares. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Lake Street Capital started coverage on Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Woodline Partners LP acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at $2,602,000. Marshall Wace LLP acquired a new stake in shares of Aligos Therapeutics during the fourth quarter worth $2,504,000. Bank of America Corp DE grew its stake in shares of Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares during the period. Readystate Asset Management LP grew its stake in shares of Aligos Therapeutics by 48.5% during the third quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after purchasing an additional 66,331 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Aligos Therapeutics by 22.8% during the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after purchasing an additional 31,913 shares during the period. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Price Performance

ALGS stock opened at $5.28 on Tuesday. The business has a fifty day moving average price of $6.33 and a 200 day moving average price of $7.70. Aligos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $13.69. The stock has a market capitalization of $32.68 million, a price-to-earnings ratio of -0.61 and a beta of 2.25.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The firm had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. On average, equities analysts expect that Aligos Therapeutics will post -7.47 earnings per share for the current fiscal year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.